Literature DB >> 1918947

Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG.

E N Janoff1, W D Hardy, P D Smith, S M Wahl.   

Abstract

To evaluate the integrity of humoral immunologic memory among persons with HIV infection, we measured the levels, specificity, and functional affinity of circulating antibodies to vaccine-related recall Ag, tetanus (TT) and diphtheria toxoids (DT), and to naturally acquired measles virus, in sera from 17 HIV-seronegative control subjects, 17 asymptomatic HIV-seropositive patients, and 10 patients with AIDS. Preimmunization levels of TT- and measles-specific IgG were similar in all groups, although DT-specific IgG was lower in AIDS patients. Four wk after immunization with TT3 and DT, all groups showed significantly increased specific antibody levels (p less than 0.02). The asymptomatic HIV+ patients and control subjects achieved similar peak serum levels of TT-specific IgG (102 +/- 32 and 169 +/- 36 micrograms/ml, respectively). In contrast, the AIDS patients had lower peak values of both TT- and DT- specific IgG (p less than 0.05). Peak levels correlated directly with the number of CD4+ T cells (p less than 0.05). However, 80 to 100% of all participants tested, independent of HIV status, showed higher levels of TT- and DT-specific IgG 6 mo after immunization compared with preimmunization levels. The antitoxoid antibodies were specific as they did not cross-react with other Ag in competitive inhibition experiments. In addition, all groups exhibited antibodies to TT and DT both pre- and postimmunization of equivalent functional affinity (avidity) (Kd = 10(-10)-10(-11) mol/liter). We conclude that, in contrast to the profoundly depressed humoral responses to new Ag, persons with asymptomatic HIV infection retain humoral immunity to certain recall Ag. These levels of specific IgG to three recall Ag are not proportional to elevated levels of total serum IgG in HIV-infected patients. In addition, many patients with HIV respond to challenge with recall Ag by producing significant amounts of high affinity IgG that may persist over time.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918947

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Vaccines against nicotine: how effective are they likely to be in preventing smoking?

Authors:  F J Vocci; C N Chiang
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Immunoglobulin G (IgG) subclass distribution and IgG1 avidity of antibodies in human immunodeficiency virus-infected individuals after revaccination with tetanus toxoid.

Authors:  F P Kroon; M J van Tol; C M Jol-van der Zijde; R van Furth; J T van Dissel
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Antibody-enhanced pneumococcal adherence requires IgA1 protease.

Authors:  Jeffrey N Weiser; Deborah Bae; Claudine Fasching; Ronald W Scamurra; Adam J Ratner; Edward N Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

4.  Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae.

Authors:  Claudine E Fasching; Tracy Grossman; Blaise Corthésy; Andrew G Plaut; Jeffrey N Weiser; Edward N Janoff
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

5.  Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region.

Authors:  Nicholas J Mantis; Jana Palaia; Ann J Hessell; Simren Mehta; Zhiyi Zhu; Blaise Corthésy; Marian R Neutra; Dennis R Burton; Edward N Janoff
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

Review 6.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

7.  Impaired haemophilus influenzae type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants.

Authors:  James T Gaensbauer; Jeremy T Rakhola; Carolyne Onyango-Makumbi; Michael Mubiru; Jamie E Westcott; Nancy F Krebs; Edwin J Asturias; Mary Glenn Fowler; Elizabeth McFarland; Edward N Janoff
Journal:  Clin Vaccine Immunol       Date:  2014-10-08

8.  Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes.

Authors:  E N Janoff; C Fasching; J M Orenstein; J B Rubins; N L Opstad; A P Dalmasso
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

9.  High predictive value of Toxoplasma gondii IgG antibody levels in HIV-infected patients for diagnosis of cerebral toxoplasmosis.

Authors:  C Hellerbrand; F D Goebel; R Disko
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

Review 10.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.